Stock Overview

Beam Therapeutics Inc (BEAM)

NASDAQ · Healthcare · Biotechnology

Beam Therapeutics Inc is a Healthcare company with a market capitalization of $3.58B.

Market Cap
$3.58B
Price/Sales
21.8
Price/Book
3.1
EV/EBITDA
-7.0
Beta
2.20
EPS (TTM)
$-0.49
Profit Margin
-40.2%
ROE
-5.8%
52W High
$36.88
52W Low
$15.60

5-Year Price History

Latest Annual Financials · FY ending December 31, 2025

Revenue
$139.74M
Gross Profit
$117.45M
Operating Income
-$383.69M
Net Income
-$79.99M
Free Cash Flow
-$360.05M
Total Debt
$14.36M
Cash & Equivalents
$294.94M
Shareholder Equity
$1.24B

Recent Quarterly Earnings (EPS)

QuarterReportedActual EPSEstimateSurprise
Q1 2026May 7, 2026$-0.91$-1.01+9.9%
Q4 2025February 24, 2026$2.33$-1.01+330.7%
Q3 2025November 4, 2025$-1.10$-1.01-8.9%
Q2 2025August 5, 2025$-1.00$-1.09+8.3%
Q1 2025May 6, 2025$-1.24$-1.17-6.0%
Q4 2024February 25, 2025$-1.09$-1.22+10.3%

Other Biotechnology Stocks

Frequently Asked Questions

What is Beam Therapeutics Inc's market cap?

As of June 29, 2026, Beam Therapeutics Inc (BEAM) has a market capitalization of $3.58B.

Does Beam Therapeutics Inc pay a dividend?

Beam Therapeutics Inc does not currently pay a dividend.

What sector is BEAM in?

Beam Therapeutics Inc is in the Healthcare sector, specifically the Biotechnology industry.

What was Beam Therapeutics Inc's revenue?

In its latest reported fiscal year (ending December 31, 2025), Beam Therapeutics Inc reported revenue of $139.74M and net income of -$79.99M.

Ask your own questions about BEAM

Try mrmarket.ai free

Data as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.